Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813758 | 1.00 | TSHR (0.35) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL30897118 | 0.77 | CA12 (0.33) | TSHRKMT2ACA12CA9CA1 | |
| SCHEMBL18306706 | 0.73 | NPC1 (0.31) | TSHRKMT2ACA12CA9CA1 | |
| SCHEMBL2816219 | 0.72 | POLA1 (0.33) | ALDH1A1CA12CA9 | |
| SCHEMBL2816300 | 0.72 | CA12 (0.31) | CA12CA9CA1CA2 | |
| SCHEMBL2816221 | 0.72 | POLA1 (0.33) | ALDH1A1CA12CA9 | |
| SCHEMBL8354298 | 0.68 | CA12 (0.42) | TSHRKMT2AALDH1A1CA12CA9 | |
| SCHEMBL11548381 | 0.68 | CA12 (0.42) | TSHRKMT2ACA12CA9CA1 | |
| SCHEMBL11548379 | 0.68 | CA12 (0.42) | TSHRKMT2ACA12CA9CA1 | |
| SCHEMBL2290500 | 0.68 | CA12 (0.42) | TSHRKMT2ACA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318804-B2 | Antiviral activity of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-11-27 | — | — | US | disclosed |
| US-8236853-B1 | Formation of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236853-B1 | Formation of cyclopentene nitro-ester and derivatives | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249230-A1 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES | CYP51A1, CES2, DDT | TSHR 4423/4885KMT2A 4206/4885ALDH1A1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.